Vassiliki Papadimitrakopoulou, MD After 30 years of frustration, investigators are starting to make headway in their quest to develop therapies that counteract oncogenic mutations in the KRAS gene, a high-priority target in precision medicine that has long been deemed “undruggable.” 1-3 The discovery of binding pockets on a mutant […]
